Trial of Romidepsin and Bortezomib for Multiple Myeloma

NCT00765102 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped There was a change in the Sponsor's research strategy; safety concerns were not a factor.

Conditions

Multiple Myeloma

Interventions

DRUG: Bortezomib
DRUG: Romidepsin

Sponsor

Celgene